CRTC1 and autosomal dominant polycystic kidney disease: As NU7441 did not affect the number of viable cells at a concentration of 0.04 μM of NU7441 in any cell line, we postulated that this dose, combined with an equivalent sub-therapeutic dose of sirolimus, might be efficacious and potentially be a strategy to overcome the toxicity of using TORC1 inhibitors alone in human ADPKD [28,29].